New drug cocktail aims to shrink tough prostate tumors before surgery

NCT ID NCT05726292

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a drug called relacorilant to standard hormone therapy and enzalutamide can better shrink high-risk prostate cancer before surgery. About 90 people whose cancer has not responded to standard treatments will take the study drugs for 24 weeks, then have their prostate removed. Researchers will check if the tumor is gone or nearly gone at that point, and follow participants for about 3 years to see if the cancer stays away.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Chicago Comprehensive Cancer Center

    RECRUITING

    Chicago, Illinois, 60453, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Texas Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact